• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Research

Independent equity research and analysis from our analyst team

Research

Independent equity research and analysis from our analyst team

Nightingale: We factored the project delay into our estimates
Research21 hours ago by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health
Puuilo Q1'26: Spot on
Research22 hours ago by
Arttu Heikura

Puuilo Q1'26: Spot on

Virtually all of the company's key metrics developed in a more positive direction.

Puuilo
Kemira: Ökade kostnader urholkar marginalen
Researchyesterday by
Petri Gostowski

Kemira: Ökade kostnader urholkar marginalen

Kemira utfärdade på onsdagen en vinstvarning, med hänvisning till ökade råvaru- och transportkostnader orsakade av kriget i Iran.

Kemira

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Suominen: Share issue in figures, valuation still high
Researchyesterday by
Rauli Juva

Suominen: Share issue in figures, valuation still high

We updated the impact of the share issue on our estimates, but operationally our assumptions remained unchanged.

Suominen
Hafnia (Investment case): Q1 2026 delivers strong cash flow and dividends amid geopolitical disruption
Research6/10/2026, 2:10 PM by
Rasmus Køjborg, William Jørck

Hafnia (Investment case): Q1 2026 delivers strong cash flow and dividends amid geopolitical disruption

Following Hafnia's Q1 2026 quarterly report, we have updated our investment case on the company. Our updated investment case covers the key investment reasons, risks, and valuation perspective relative to product tanker peers.

Hafnia
Sitowise Group: Divestment drops Swedish millstone
Research6/10/2026, 7:14 AM by
Olli Vilppo

Sitowise Group: Divestment drops Swedish millstone

Sitowise announced yesterday that it is selling its Swedish technical consulting operations to Sweco.

Sitowise Group
Keskisuomalainen omfattande analys: Utdelning och digital omställning i fokus för berättelsen
Extensive research6/10/2026, 4:10 AM by
Arttu Heikura

Keskisuomalainen omfattande analys: Utdelning och digital omställning i fokus för berättelsen

Investeringscaset är beroende av en lyckad digital omställning och anpassning av den vikande verksamheten.

Keskisuomalainen
Duell omfattande analys: Söker en U-sväng
Extensive research6/9/2026, 6:23 AM by
Tommi Saarinen

Duell omfattande analys: Söker en U-sväng

Vi har höjt våra estimat för innevarande år, men balansräkningen förblir stram.

Duell
Terveystalo: Ytterligare styrka söks från optikverksamheten
Research6/9/2026, 4:00 AM by
Roni Peuranheimo

Terveystalo: Ytterligare styrka söks från optikverksamheten

I och med förvärven av Silmäasema och Hohde rör sig Terveystalo från att vara en stabil utdelare mot en tydligare tillväxtinriktning.

Terveystalo
Danske Bank (Investment case): Q1 2026 confirms resilient earnings as Forward '28 raises the bar
Research6/8/2026, 3:08 PM by
Rasmus Køjborg, William Jørck

Danske Bank (Investment case): Q1 2026 confirms resilient earnings as Forward '28 raises the bar

Following Danske Bank's Q1 2026 interim report, we have updated our investment case on the company. Our updated investment case covers the key investment reasons, risks, and valuation perspective relative to peers across Nordic large-cap banking.

Danske Bank
Aurora Group Intiation of Coverage: Monitoring of Northern Lights starts
Extensive research6/8/2026, 8:44 AM by
Olli Vilppo

Aurora Group Intiation of Coverage: Monitoring of Northern Lights starts

Auroora's compounder story is in its early stages, but the company's playbook for achieving ambitious targets is in order.

Auroora Group
Alexandria: Pojken har bastat även på Esplanaden
Research6/7/2026, 11:00 AM by
Sauli Vilén

Alexandria: Pojken har bastat även på Esplanaden

Alexandrias första del av året har varit mycket stark och våra vinstestimat har stigit kraftigt. I förhållande till de höjda estimaten är aktien förmånlig.

Alexandria Group
Atria: Värderingen sjönk till en förmånlig nivå, trots att inflationen tär
Research6/5/2026, 5:00 AM by
Rauli Juva, Pauli Lohi

Atria: Värderingen sjönk till en förmånlig nivå, trots att inflationen tär

I och med kursnedgången har företagets värdering (t.ex. 2026 P/E och EV/EBIT 9x) enligt vår mening tyngts ner till en förmånlig nivå.

Atria
Aspocomp omfattande analys: Ny tillväxtfas driven av stark efterfrågan
Extensive research6/4/2026, 3:48 PM by
Kaisa Vanha-Perttula

Aspocomp omfattande analys: Ny tillväxtfas driven av stark efterfrågan

Vi förväntar oss att vinsten kommer att göra en tydlig uppåtgående korrigering under de närmaste åren, men vi anser att en betydande del av denna utveckling redan är inprisad i aktien.

Aspocomp Group
Metacon: Securing funding to fuel the next growth phase
Research6/4/2026, 5:57 AM by
Lucas Mattsson

Metacon: Securing funding to fuel the next growth phase

In our view, the recently announced capital raise reduces the financing risks and should give the company the runway to execute its order backlog and help convert parts of its sales pipeline, at least in the short term.

Metacon
Nightingale: Nightingale sings to a deaf market
Research6/4/2026, 6:36 AM by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
North Media (Investment Case): Improved Q1 profit, but lowered guidance ceiling
Research6/3/2026, 9:54 AM by
Jacob Frehr, Rasmus Køjborg

North Media (Investment Case): Improved Q1 profit, but lowered guidance ceiling

Today, we publish our updated North Media A/S investment case following the Q1 2026 report. North Media delivered improved Q1 profitability with EBIT rising to DKK 4m and EBITDA up 72%, though management cut the top end of 2026 guidance on a weak start in SDR and BoligPortal. The stock continues to trade at a significant discount to peers, as the large securities portfolio results in a very low implied EV, leaving the operating business valued at close to zero.

North Media
Martela: Flyttlasset lättade, men balansräkningen tyngs fortsatt
Research6/3/2026, 6:12 AM by
Thomas Westerholm

Martela: Flyttlasset lättade, men balansräkningen tyngs fortsatt

Vi har beaktat försäljningen av Martelas flyttjänstverksamhet i våra estimat, vilket höjde vårt rapporterade vinstestimat för innevarande år, men sänkte de operativa estimaten.

Martela
Herantis: Clarity on efficacy study details
Research6/3/2026, 8:21 AM by
Antti Siltanen

Herantis: Clarity on efficacy study details

The study will produce high-quality data on the safety of the Parkinson's disease drug candidate and preliminary data on its efficacy.

Herantis Pharma
Curasight (Investment Case): Four high-value read-outs on track for H2 2026
Research6/2/2026, 10:00 AM by
Michael Friis, Victor Skriver

Curasight (Investment Case): Four high-value read-outs on track for H2 2026

In connection with Curasight's Q1 2026 interim report, we have updated our Investment Case. Our investment case covers the key investment reasons, risks, and valuation perspectives.

Curasight